These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Ritonavir, Abbott protease inhibitor, approved.
    Journal: AIDS Treat News; 1996 Mar 15; (no 243):2-3. PubMed ID: 11363300.
    Abstract:
    Abbott Laboratories' protease inhibitor, ritonavir, received Food and Drug Administration (FDA) approval in record time, and was available in pharmacies within a week of approval. Ritonavir is the only protease inhibitor to complete clinical-endpoint trials to date, and has a proven survival benefit. However, its drawbacks include strong drug interactions, resistance and cross resistance, and liver damage. Patients are cautioned to delay protease inhibitor treatment until Merck's Crixivan is available. Information from ritonavir's package insert is included, detailing usage, drug interactions, adverse events, and cost and reimbursement information. Ritonavir is the most expensive antiretroviral drug on the market.
    [Abstract] [Full Text] [Related] [New Search]